Holen Sie sich die Stockscreener-App
8.89
0.79%
0.07
Handel nachbörslich:
8.90
0.010
+0.11%
Schlusskurs vom Vortag:
$8.82
Offen:
$8.77
24-Stunden-Volumen:
101.92K
Relative Volume:
0.59
Marktkapitalisierung:
$190.05M
Einnahmen:
$66.59M
Nettoeinkommen (Verlust:
$-104.93M
KGV:
-1.796
EPS:
-4.95
Netto-Cashflow:
$-96.48M
1W Leistung:
+2.30%
1M Leistung:
+25.21%
6M Leistung:
+22.79%
1J Leistung:
-26.77%
1-Tages-Spanne:
$8.50
$8.961
1-Wochen-Bereich:
$8.33
$9.17
52-Wochen-Spanne:
$4.09
$13.37
Enanta Pharmaceuticals Inc Stock (ENTA) Company Profile
Firmenname
Enanta Pharmaceuticals Inc
Sektor
Branche
Telefon
617 607 0800
Adresse
4 KINGSBURY AVENUE, WATERTOWN, MA
Vergleichen Sie ENTA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ENTA
Enanta Pharmaceuticals Inc
|
8.89 | 192.40M | 66.59M | -104.93M | -96.48M | -4.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Enanta Pharmaceuticals Inc Stock (ENTA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-28 | Fortgesetzt | H.C. Wainwright | Buy |
| 2023-08-09 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2023-08-08 | Herabstufung | Jefferies | Buy → Hold |
| 2022-12-09 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-07-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2022-06-01 | Hochstufung | Evercore ISI | Underperform → In-line |
| 2021-10-07 | Eingeleitet | Jefferies | Buy |
| 2021-09-09 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2021-01-29 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2020-11-24 | Eingeleitet | Evercore ISI | Underperform |
| 2020-08-28 | Fortgesetzt | ROTH Capital | Buy |
| 2020-08-26 | Eingeleitet | Piper Sandler | Overweight |
| 2020-07-27 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2020-03-17 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2019-11-22 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-09-26 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2019-05-24 | Eingeleitet | Wolfe Research | Outperform |
| 2019-04-23 | Hochstufung | Berenberg | Hold → Buy |
| 2018-12-13 | Eingeleitet | Berenberg | Hold |
| 2018-06-06 | Eingeleitet | ROTH Capital | Buy |
| 2018-02-08 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-01-02 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2017-11-21 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2017-07-11 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2016-04-28 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2016-02-09 | Bestätigt | Barclays | Underweight |
| 2015-10-23 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2015-10-23 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
Alle ansehen
Enanta Pharmaceuticals Inc Aktie (ENTA) Neueste Nachrichten
Using data tools to time your Enanta Pharmaceuticals Inc. exit2025 Support & Resistance & Free Fast Gain Swing Trade Alerts - Newser
How to build a custom watchlist for Enanta Pharmaceuticals Inc.Index Update & AI Enhanced Trading Alerts - Newser
Real time social sentiment graph for Enanta Pharmaceuticals Inc.Weekly Trading Summary & Safe Entry Momentum Stock Tips - Newser
What MACD and RSI say about Enanta Pharmaceuticals Inc.2025 Market WrapUp & High Accuracy Trade Signal Alerts - Newser
Enanta CFO dies after taking medical leave of absence - CFO Dive
Enanta Pharmaceuticals Announces the Passing of Chief Financial and Administrative Officer Paul J. Mellett Jr. - citybiz
Enanta Pharmaceuticals Appoints Interim Financial Officers - MSN
Real time pattern detection on Enanta Pharmaceuticals Inc. stockWeekly Risk Report & Growth-Oriented Investment Plans - Newser
Tools to monitor Enanta Pharmaceuticals Inc. recovery probabilityJuly 2025 PostEarnings & Verified Chart Pattern Signals - Newser
Enanta Pharmaceuticals Announces the Passing of its Beloved and Respected Longtime Chief Financial a - PharmiWeb.com
Live market analysis of Enanta Pharmaceuticals Inc.Portfolio Profit Report & Weekly Stock Performance Updates - Newser
Enanta Pharmaceuticals announces passing of longtime CFO Paul Mellett - Investing.com
Will Enanta Pharmaceuticals Inc. see short term momentum2025 Trade Ideas & Weekly Top Performers Watchlists - Newser
Enanta Pharmaceuticals, Inc.'s (NASDAQ:ENTA) Price Is Right But Growth Is Lacking After Shares Rocket 27% - simplywall.st
Enanta Pharmaceuticals: Leadership Continuity and Strategic Resilience in Biotech R&D - AInvest
Enanta Pharmaceuticals Chief Financial, Administrative Officer Dies - MarketScreener
Enanta Pharmaceuticals Receives New 'Buy' Rating from WestPark Capital with $24.00 Price Target - AInvest
What recovery options are there for Enanta Pharmaceuticals Inc.Market Movement Recap & Free Low Drawdown Momentum Trade Ideas - Newser
Enanta Pharmaceuticals Announces the Passing of its Beloved and Respected Longtime Chief Financial and Administrative Officer Paul J. Mellett Jr. | ENTA Stock News - GuruFocus
Enanta Pharmaceuticals Announces Passing of Chief Financial and Administrative Officer Paul J. Mellett Jr. - AInvest
Two Decades of Leadership: Enanta Pharmaceuticals Mourns Loss of CFO Who Helped Cure 1M+ HCV Patients - Stock Titan
Historical volatility pattern of Enanta Pharmaceuticals Inc. visualizedJuly 2025 Sector Moves & Reliable Entry Point Alerts - Newser
Measuring Enanta Pharmaceuticals Inc.’s beta against major indicesJuly 2025 Momentum & Accurate Entry and Exit Point Alerts - Newser
Published on: 2025-09-03 03:49:04 - Newser
Short interest data insights for Enanta Pharmaceuticals Inc.Insider Selling & Precise Buy Zone Tips - Newser
How to build a dashboard for Enanta Pharmaceuticals Inc. stockJuly 2025 Macro Moves & Advanced Technical Signal Analysis - Newser
Using data filters to optimize entry into Enanta Pharmaceuticals Inc.Index Update & Technical Pattern Based Buy Signals - Newser
Can you recover from losses in Enanta Pharmaceuticals Inc.2025 Investor Takeaways & Expert Approved Trade Ideas - Newser
Is Enanta Pharmaceuticals Inc. reversing from oversold territory2025 Technical Patterns & AI Driven Price Predictions - Newser
Key resistance and support levels for Enanta Pharmaceuticals Inc.July 2025 Short Interest & Long-Term Growth Plans - Newser
Is Enanta Pharmaceuticals Inc. forming a breakout patternJuly 2025 Movers & Technical Buy Zone Confirmations - khodrobank.com
What’s the outlook for Enanta Pharmaceuticals Inc.’s sector2025 Momentum Check & Free High Accuracy Swing Entry Alerts - khodrobank.com
Can momentum traders help lift Enanta Pharmaceuticals Inc.2025 Sector Review & Consistent Profit Trading Strategies - Newser
Enanta Pharma (ENTA) Receives New 'Buy' Rating from WestPark Capital | ENTA Stock News - GuruFocus
Enanta Pharmaceuticals: WestPark Capital initiates coverage with a Buy rating and $24 PT. - AInvest
How to manage a losing position in Enanta Pharmaceuticals Inc.2025 Price Action Summary & Community Driven Trade Alerts - Newser
Aug Chart Watch: Will Enanta Pharmaceuticals Inc. be affected by tariffsJuly 2025 Retail & Weekly High Return Forecasts - khodrobank.com
Can Enanta Pharmaceuticals Inc. rally from current levelsWeekly Profit Report & AI Based Buy and Sell Signals - Newser
Visualizing Enanta Pharmaceuticals Inc. stock with heatmapsWeekly Trade Report & Weekly High Potential Stock Alerts - Newser
What recovery options are there for Enanta Pharmaceuticals IncJuly 2025 WrapUp & Fast Gain Stock Tips - Newser
Finanzdaten der Enanta Pharmaceuticals Inc-Aktie (ENTA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Enanta Pharmaceuticals Inc-Aktie (ENTA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Kieffer Tara Lynn | Chief Product Strategy Officer |
Dec 06 '24 |
Sale |
8.06 |
2,283 |
18,401 |
29,305 |
| Luu Brendan | Chief Business Officer |
Dec 06 '24 |
Sale |
8.06 |
2,283 |
18,401 |
36,047 |
| Rottinghaus Scott T. | Chief Medical Officer |
Dec 06 '24 |
Sale |
8.06 |
866 |
6,980 |
17,918 |
| Or Yat Sun | Chief Scientific Officer |
Dec 06 '24 |
Sale |
8.06 |
2,591 |
20,883 |
369,109 |
| MELLETT PAUL J | Chief Fin. & Admin Officer |
Dec 06 '24 |
Sale |
8.06 |
2,591 |
20,883 |
91,710 |
| Luly Jay R. | President and CEO |
Dec 06 '24 |
Sale |
8.06 |
5,142 |
41,445 |
801,638 |
1.75%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):